Investment analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Up 141,999,900.0 %
NASDAQ:NBRV opened at $1.42 on Monday. The company has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The business’s 50 day moving average price is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- MarketBeat Week in Review – 5/20 – 5/24
- CD Calculator: Certificate of Deposit Calculator
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- What does consumer price index measure?
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.